2026 Q1 -tulosraportti
22 päivää sitten
‧29 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 197 | - | - | ||
| 1 303 | - | - | ||
| 125 | - | - | ||
| 20 000 | - | - | ||
| 16 788 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 136 448 | 136 448 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 136 448 | 136 448 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 päivä sittenFrom DNB Carnegie's NEWS FLASH NOTE on June 9, 2026 * Focuses on KDIGO guidelines as the next trigger. They have changed the timing from 2H to Q3 2026 **Fair value interval of DKK0.5–3.0 per share over 12 months is reiterated. From DNB Carnegie's RESULTS UPDATE NOTE on May 21, 2026 ***Acquisition a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. Based on our 2032 estimates, we calculate that this would imply an equity value of ~DKK4.7–5.6/share (discounted with a 16.5% WACC). Let's say the company is acquired in 3-5 years at 5 DKK/share (mid-point of DNB Carnegie's estimate). I.e. 4x current price. Worth waiting for? Important assumptions are falling into place with the positive announcements from the FDA this year and guidelines from KDIGO later this year.
·1 päivä sittenWatch or rewatch https://www.youtube.com/watch?v=tmGjhrI-SLY·1 päivä sittenI can well understand that it sounds completely crazy Mathias, what I wrote yesterday, regarding RUO If it's completely off the mark. 1. where do the huge revenues come from, which management says are coming, KW said verbatim, that there will be, ramp up, just for the sake of good order, I looked it up, and it literally means. rapidly increases its activity, production or sales. 2. If the following is completely crazy Matias and it's pure fantasy on my part, how do we then explain, this wild revenue that KW said would come, when BP will only sell the NGAL test to children's hospitals, and adult hospitals, are excluded? 3. BP has also not downgraded the number of hospitals 60+ They " only" need 900 patients and they have that, at the 4 university hospitals, which they got in Q1. So how will they be able to achieve 60+ hospitals in 2026, when they don't need more adult hospitals, to satisfy FDA's requirements, for 900 patients? I'd be happy to provide an answer.. There can only be 60+ hospitals, and CB and KW can only ramp up, if they go under FDA's radar, and use the method below. Because so many tests. will not be needed at children's hospitals throughout the USA, for BP to meet their guidance? If you have other suggestions, how they can ramp up, now that FDA has excluded, that Bioporto may sell to adult hospitals, I would be happy to read it. If you don't have an alternative suggestion, but only come with sour remarks, then you don't need to, spend energy on, writing anything at all.- ·2 päivää sittenOnly for those of you who share my interest in finding out what hospitals do to avoid being sued. Everyone else stop reading. Now the penny has finally dropped for me. I have finally gotten an answer as to why it is best to sell the NGAL test as RUO in the USA at the moment. The above is a question we investors have never had answered, even though we ask about it often. Now that the FDA has done the unthinkable, kicking KDIGO's strong recommendations to the curb (see link from previous post) and due to political pressure from Donald Trump (see link from previous post) delaying the NGAL test for adults from being approved in the USA. I have dug a bit to find out if there is anything hospitals will do to avoid lawsuits from patients and relatives. Because it is not the FDA that becomes the victim of a lawsuit, it is the hospitals. Lawyers will never directly accuse a hospital of not implementing the NGAL test as long as the FDA has not approved the test, but they will accuse hospitals of not monitoring well enough, being too slow to react, etc. Lawyers will not use the words NGAL test, but everything else that revolves around the NGAL test's properties, and in this way, accuse hospitals of not being able to react as quickly as the NGAL test. As you can see, it's about large sums of money. To avoid the feared lawsuits and settlements, there is a grey zone that both BP and the hospitals are treading in on tiptoes. Hospitals large enough to have an advanced laboratory can get permission to introduce the NGAL test into their treatment systems, but only approved for research (RUO); every time hospitals use this test on their patients, it is naturally only for research. Hospitals will integrate the NGAL test into their treatment system, but only for research, naturally, to avoid lawsuits and settlements. The above also answers another wonder of mine: how can it be that there is strong growth in the USA when it is only for research? That is because those hospitals that have an advanced enough laboratory to help Bioporto in research also secretly use the test on all their other patients where the test is beneficial. The above is the reason why both PME and CB only come with some mumbling and incomprehensible words as to why RUO is good for BP's earnings. The FDA is naturally aware of this, but as long as the NGAL test saves lives and health, the bear will remain in its den.·21 t sittenAn amateur who nevertheless was 100% right, where others lost 100%.
·21 t sittenWonder how many of your First North investments have gone bankrupt, you don't dare to show your portfolio, so everything you say is just hot air 😘 
·2 päivää sittenTo those of you who have a lot of money tied up in bioporto. Then I can't help but think that if it's going to take 2 years before anything happens with potential approvals, stock price increases, etc., then the money could be invested in many other things in the meantime? Economically speaking, it probably doesn't make much sense to have the money "standing still"? Because the stock price will probably hardly climb significantly before 2028 if things go as bioporto hopes? Anyone who wants to enlighten me on what they think? 🤔
·2 päivää sittenNo, I don't agree with that. The only thing that can truly destroy Bioporto at this share price level is if the adult study fails.
·2 päivää sitten · MuokattuPm_invest It's good to have different assessments. I now see the upcoming Kdigo as something investors attach great value to, both up and down. But I certainly find it interesting that you don't think it will affect the price. We will soon get an answer.- ·2 päivää sittenCongratulations to CEO, Carsten Buhl, who in approx. 6 months has delivered 2 postponements of the financial target for cash flow Original plan H2 2027 1st postponement H1 2028 2nd postponement H2 2028 How many more can Carsten possibly manage to deliver in the coming 24 months...... 1, 2 or 3? The clock is ticking and patent expiry is getting closer and closer, while BP is burning millions.·2 päivää sittenProgression, there is a reason why very many small investors lose money, one of them is that many small investors are not at all interested in facts but only in hearing what they want to hear.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
22 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sittenFrom DNB Carnegie's NEWS FLASH NOTE on June 9, 2026 * Focuses on KDIGO guidelines as the next trigger. They have changed the timing from 2H to Q3 2026 **Fair value interval of DKK0.5–3.0 per share over 12 months is reiterated. From DNB Carnegie's RESULTS UPDATE NOTE on May 21, 2026 ***Acquisition a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. Based on our 2032 estimates, we calculate that this would imply an equity value of ~DKK4.7–5.6/share (discounted with a 16.5% WACC). Let's say the company is acquired in 3-5 years at 5 DKK/share (mid-point of DNB Carnegie's estimate). I.e. 4x current price. Worth waiting for? Important assumptions are falling into place with the positive announcements from the FDA this year and guidelines from KDIGO later this year.
- ·1 päivä sittenWatch or rewatch https://www.youtube.com/watch?v=tmGjhrI-SLY·1 päivä sittenI can well understand that it sounds completely crazy Mathias, what I wrote yesterday, regarding RUO If it's completely off the mark. 1. where do the huge revenues come from, which management says are coming, KW said verbatim, that there will be, ramp up, just for the sake of good order, I looked it up, and it literally means. rapidly increases its activity, production or sales. 2. If the following is completely crazy Matias and it's pure fantasy on my part, how do we then explain, this wild revenue that KW said would come, when BP will only sell the NGAL test to children's hospitals, and adult hospitals, are excluded? 3. BP has also not downgraded the number of hospitals 60+ They " only" need 900 patients and they have that, at the 4 university hospitals, which they got in Q1. So how will they be able to achieve 60+ hospitals in 2026, when they don't need more adult hospitals, to satisfy FDA's requirements, for 900 patients? I'd be happy to provide an answer.. There can only be 60+ hospitals, and CB and KW can only ramp up, if they go under FDA's radar, and use the method below. Because so many tests. will not be needed at children's hospitals throughout the USA, for BP to meet their guidance? If you have other suggestions, how they can ramp up, now that FDA has excluded, that Bioporto may sell to adult hospitals, I would be happy to read it. If you don't have an alternative suggestion, but only come with sour remarks, then you don't need to, spend energy on, writing anything at all.
- ·2 päivää sittenOnly for those of you who share my interest in finding out what hospitals do to avoid being sued. Everyone else stop reading. Now the penny has finally dropped for me. I have finally gotten an answer as to why it is best to sell the NGAL test as RUO in the USA at the moment. The above is a question we investors have never had answered, even though we ask about it often. Now that the FDA has done the unthinkable, kicking KDIGO's strong recommendations to the curb (see link from previous post) and due to political pressure from Donald Trump (see link from previous post) delaying the NGAL test for adults from being approved in the USA. I have dug a bit to find out if there is anything hospitals will do to avoid lawsuits from patients and relatives. Because it is not the FDA that becomes the victim of a lawsuit, it is the hospitals. Lawyers will never directly accuse a hospital of not implementing the NGAL test as long as the FDA has not approved the test, but they will accuse hospitals of not monitoring well enough, being too slow to react, etc. Lawyers will not use the words NGAL test, but everything else that revolves around the NGAL test's properties, and in this way, accuse hospitals of not being able to react as quickly as the NGAL test. As you can see, it's about large sums of money. To avoid the feared lawsuits and settlements, there is a grey zone that both BP and the hospitals are treading in on tiptoes. Hospitals large enough to have an advanced laboratory can get permission to introduce the NGAL test into their treatment systems, but only approved for research (RUO); every time hospitals use this test on their patients, it is naturally only for research. Hospitals will integrate the NGAL test into their treatment system, but only for research, naturally, to avoid lawsuits and settlements. The above also answers another wonder of mine: how can it be that there is strong growth in the USA when it is only for research? That is because those hospitals that have an advanced enough laboratory to help Bioporto in research also secretly use the test on all their other patients where the test is beneficial. The above is the reason why both PME and CB only come with some mumbling and incomprehensible words as to why RUO is good for BP's earnings. The FDA is naturally aware of this, but as long as the NGAL test saves lives and health, the bear will remain in its den.·21 t sittenAn amateur who nevertheless was 100% right, where others lost 100%.·21 t sittenWonder how many of your First North investments have gone bankrupt, you don't dare to show your portfolio, so everything you say is just hot air 😘
- ·2 päivää sittenTo those of you who have a lot of money tied up in bioporto. Then I can't help but think that if it's going to take 2 years before anything happens with potential approvals, stock price increases, etc., then the money could be invested in many other things in the meantime? Economically speaking, it probably doesn't make much sense to have the money "standing still"? Because the stock price will probably hardly climb significantly before 2028 if things go as bioporto hopes? Anyone who wants to enlighten me on what they think? 🤔·2 päivää sittenNo, I don't agree with that. The only thing that can truly destroy Bioporto at this share price level is if the adult study fails.·2 päivää sitten · MuokattuPm_invest It's good to have different assessments. I now see the upcoming Kdigo as something investors attach great value to, both up and down. But I certainly find it interesting that you don't think it will affect the price. We will soon get an answer.
- ·2 päivää sittenCongratulations to CEO, Carsten Buhl, who in approx. 6 months has delivered 2 postponements of the financial target for cash flow Original plan H2 2027 1st postponement H1 2028 2nd postponement H2 2028 How many more can Carsten possibly manage to deliver in the coming 24 months...... 1, 2 or 3? The clock is ticking and patent expiry is getting closer and closer, while BP is burning millions.·2 päivää sittenProgression, there is a reason why very many small investors lose money, one of them is that many small investors are not at all interested in facts but only in hearing what they want to hear.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 197 | - | - | ||
| 1 303 | - | - | ||
| 125 | - | - | ||
| 20 000 | - | - | ||
| 16 788 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 136 448 | 136 448 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 136 448 | 136 448 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
22 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sittenFrom DNB Carnegie's NEWS FLASH NOTE on June 9, 2026 * Focuses on KDIGO guidelines as the next trigger. They have changed the timing from 2H to Q3 2026 **Fair value interval of DKK0.5–3.0 per share over 12 months is reiterated. From DNB Carnegie's RESULTS UPDATE NOTE on May 21, 2026 ***Acquisition a potential scenario. We see BioPorto as a potential acquisition target for large diagnostics companies. Based on historical transaction multiples in the Nordics, we believe such a deal could be executed at ~7x EV/sales or ~20x EV/EBITDA. Based on our 2032 estimates, we calculate that this would imply an equity value of ~DKK4.7–5.6/share (discounted with a 16.5% WACC). Let's say the company is acquired in 3-5 years at 5 DKK/share (mid-point of DNB Carnegie's estimate). I.e. 4x current price. Worth waiting for? Important assumptions are falling into place with the positive announcements from the FDA this year and guidelines from KDIGO later this year.
- ·1 päivä sittenWatch or rewatch https://www.youtube.com/watch?v=tmGjhrI-SLY·1 päivä sittenI can well understand that it sounds completely crazy Mathias, what I wrote yesterday, regarding RUO If it's completely off the mark. 1. where do the huge revenues come from, which management says are coming, KW said verbatim, that there will be, ramp up, just for the sake of good order, I looked it up, and it literally means. rapidly increases its activity, production or sales. 2. If the following is completely crazy Matias and it's pure fantasy on my part, how do we then explain, this wild revenue that KW said would come, when BP will only sell the NGAL test to children's hospitals, and adult hospitals, are excluded? 3. BP has also not downgraded the number of hospitals 60+ They " only" need 900 patients and they have that, at the 4 university hospitals, which they got in Q1. So how will they be able to achieve 60+ hospitals in 2026, when they don't need more adult hospitals, to satisfy FDA's requirements, for 900 patients? I'd be happy to provide an answer.. There can only be 60+ hospitals, and CB and KW can only ramp up, if they go under FDA's radar, and use the method below. Because so many tests. will not be needed at children's hospitals throughout the USA, for BP to meet their guidance? If you have other suggestions, how they can ramp up, now that FDA has excluded, that Bioporto may sell to adult hospitals, I would be happy to read it. If you don't have an alternative suggestion, but only come with sour remarks, then you don't need to, spend energy on, writing anything at all.
- ·2 päivää sittenOnly for those of you who share my interest in finding out what hospitals do to avoid being sued. Everyone else stop reading. Now the penny has finally dropped for me. I have finally gotten an answer as to why it is best to sell the NGAL test as RUO in the USA at the moment. The above is a question we investors have never had answered, even though we ask about it often. Now that the FDA has done the unthinkable, kicking KDIGO's strong recommendations to the curb (see link from previous post) and due to political pressure from Donald Trump (see link from previous post) delaying the NGAL test for adults from being approved in the USA. I have dug a bit to find out if there is anything hospitals will do to avoid lawsuits from patients and relatives. Because it is not the FDA that becomes the victim of a lawsuit, it is the hospitals. Lawyers will never directly accuse a hospital of not implementing the NGAL test as long as the FDA has not approved the test, but they will accuse hospitals of not monitoring well enough, being too slow to react, etc. Lawyers will not use the words NGAL test, but everything else that revolves around the NGAL test's properties, and in this way, accuse hospitals of not being able to react as quickly as the NGAL test. As you can see, it's about large sums of money. To avoid the feared lawsuits and settlements, there is a grey zone that both BP and the hospitals are treading in on tiptoes. Hospitals large enough to have an advanced laboratory can get permission to introduce the NGAL test into their treatment systems, but only approved for research (RUO); every time hospitals use this test on their patients, it is naturally only for research. Hospitals will integrate the NGAL test into their treatment system, but only for research, naturally, to avoid lawsuits and settlements. The above also answers another wonder of mine: how can it be that there is strong growth in the USA when it is only for research? That is because those hospitals that have an advanced enough laboratory to help Bioporto in research also secretly use the test on all their other patients where the test is beneficial. The above is the reason why both PME and CB only come with some mumbling and incomprehensible words as to why RUO is good for BP's earnings. The FDA is naturally aware of this, but as long as the NGAL test saves lives and health, the bear will remain in its den.·21 t sittenAn amateur who nevertheless was 100% right, where others lost 100%.·21 t sittenWonder how many of your First North investments have gone bankrupt, you don't dare to show your portfolio, so everything you say is just hot air 😘
- ·2 päivää sittenTo those of you who have a lot of money tied up in bioporto. Then I can't help but think that if it's going to take 2 years before anything happens with potential approvals, stock price increases, etc., then the money could be invested in many other things in the meantime? Economically speaking, it probably doesn't make much sense to have the money "standing still"? Because the stock price will probably hardly climb significantly before 2028 if things go as bioporto hopes? Anyone who wants to enlighten me on what they think? 🤔·2 päivää sittenNo, I don't agree with that. The only thing that can truly destroy Bioporto at this share price level is if the adult study fails.·2 päivää sitten · MuokattuPm_invest It's good to have different assessments. I now see the upcoming Kdigo as something investors attach great value to, both up and down. But I certainly find it interesting that you don't think it will affect the price. We will soon get an answer.
- ·2 päivää sittenCongratulations to CEO, Carsten Buhl, who in approx. 6 months has delivered 2 postponements of the financial target for cash flow Original plan H2 2027 1st postponement H1 2028 2nd postponement H2 2028 How many more can Carsten possibly manage to deliver in the coming 24 months...... 1, 2 or 3? The clock is ticking and patent expiry is getting closer and closer, while BP is burning millions.·2 päivää sittenProgression, there is a reason why very many small investors lose money, one of them is that many small investors are not at all interested in facts but only in hearing what they want to hear.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 197 | - | - | ||
| 1 303 | - | - | ||
| 125 | - | - | ||
| 20 000 | - | - | ||
| 16 788 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 136 448 | 136 448 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 136 448 | 136 448 | 0 | 0 |